ImmuCell Corporation (ICCC) AI Stock Analysis
ICCC AI stock analysis summary
AI ResearchImmuCell Corporation (ICCC) is an animal health biotechnology company focused on bovine health management solutions like First Defense. Over the trailing twelve months, the company generated $30.7M in revenue with an operating margin of 26.9%. While its trailing P/E stands at 153.6x, quarterly earnings grew 259.9% year-over-year in the period ending June 30, 2026.
- Market cap
- $97.6M
- Revenue (TTM)
- $30.7M
- P/E
- 153.6x
- 1Y return
- 72.0% S&P 500 16.8%
- Avg. target
- $14.00 30.2% vs last close
Bull case
- Quarterly earnings increased 259.9% year-over-year in the latest quarter ending June 30, 2026.
- Free cash flow turned positive at $1.2M in FY2025 alongside operating cash flow of $2.5M.
- The analyst mean price target of $14.00 implies 30.2% upside from the last closing price of $10.75.
Bear case
- ImmuCell trades at a trailing P/E of 153.6x, higher than the US-listed Healthcare peer median of 24.6x.
- The company reported annual net losses from FY2021 through FY2025, including net income of -$1.0M in FY2025.
- ImmuCell recorded 0 EPS beats across the last four quarters.
What ImmuCell does
Headquartered in Portland, Maine, ImmuCell Corporation develops, manufactures, and markets animal health products for dairy and beef cattle. Established in 1982, the company distributes its solutions through a network of animal health distributors. Its flagship offering, First Defense, is an orally administered preventive solution against scours in newborn calves, while Tri-Shield First Defense delivers passive antibody protection against E. coli, coronavirus, and rotavirus. ImmuCell also provides Dual-Force First Defense for nutritional supplementation, the California Mastitis Test for diagnostic milk screening, and is developing Re-Tain, an intramammary treatment utilizing Nisin for subclinical mastitis in lactating dairy cows.
Growth and profitability
From FY2020 to FY2025, ImmuCell achieved a 5-year revenue CAGR of 12.5%. Annual revenue increased from $19.2M in FY2021 to $27.6M in FY2025, supported by a 51.6% rise in FY2024. Gross margin improved to 41.4% in FY2025 after falling to 25.2% in FY2023. Operating margin reached 6.0% in FY2025, though net income remained negative at -$1.0M with an EPS of -$0.11. Over the trailing twelve months ending June 30, 2026, revenue reached $30.7M, with an operating margin of 26.9% and a profit margin of 2.6%. For the latest quarter ending June 30, 2026, quarterly revenue rose 11.5% and quarterly earnings increased 259.9% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, ImmuCell held $8.9M in cash and short-term investments against total debt of $12.4M, resulting in net debt of $3.6M. The company maintains a current ratio of 4.75 and a debt-to-equity ratio of 0.40 on shareholders' equity of $31.4M. In FY2025, operating cash flow was $2.5M and free cash flow turned positive at $1.2M, with capital expenditures at $1.3M. Over the past five years, the company's share count increased 20.0%.
Valuation and performance
At a market cap of $97.6M and enterprise value of $94.3M, ImmuCell trades at a trailing P/E of 153.6x, compared to the median of 24.6x for its US-listed Healthcare peers. Its EV to EBITDA ratio is 25.8x versus the peer median of 12.0x, while its price-to-sales multiple of 3.2x is below the peer median of 4.1x. Over the past year, ICCC delivered a return of 72.0%, outperforming the S&P 500 (SPY) return of 16.8%. Over five years, the stock returned 15.8% compared to 83.0% for the index.
What analysts expect
Analysts maintain a mean price target of $14.00 for ImmuCell, representing a 30.2% premium over its last close of $10.75 on October 16, 2026. The company registered 0 EPS beats over the last four quarters. ImmuCell is scheduled to report its next earnings on November 12, 2026, with trailing twelve-month EPS currently reported at $0.07.
Key risks and what to watch
- Total debt of $12.4M exceeds cash and short-term investments of $8.9M, leaving net debt at $3.6M as of June 30, 2026.
- Shareholder dilution has been present, with the share count expanding 20.0% over the past five years.
- Research and development spending decreased from $4.5M in FY2022 to $3.0M in FY2025.
- The stock's 5-year return of 15.8% lagged the S&P 500 return of 83.0%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ICCC AI stock analysis
This page is an AI-written research summary of ImmuCell Corporation (ICCC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ICCC income statement, ICCC balance sheet, ICCC key metrics, ICCC chart. See the ICCC stock overview for the latest quote and news.
ICCC AI stock analysis FAQ
What products does ImmuCell Corporation sell?
ImmuCell's primary product is First Defense, an oral treatment that prevents scours in newborn calves. The company also sells Tri-Shield First Defense, Dual-Force First Defense, the California Mastitis Test, and is developing Re-Tain for mastitis treatment.
Does ImmuCell Corporation pay a dividend?
ImmuCell does not pay a dividend. Capital is reinvested into operations and capital expenditures, which were $1.3M in FY2025.
What is ImmuCell's net debt position?
As of June 30, 2026, ImmuCell held $8.9M in cash and short-term investments against $12.4M in total debt, resulting in net debt of $3.6M. Its debt-to-equity ratio is 0.40.
When does ImmuCell report earnings next?
ImmuCell's next earnings date is November 12, 2026. In the latest quarter ending June 30, 2026, quarterly revenue grew 11.5% year-over-year.